92 related articles for article (PubMed ID: 18610755)
1. [Metformin and type 2 diabetes: the UKPDS experience].
Leverve XM
Journ Annu Diabetol Hotel Dieu; 2007; ():5-11. PubMed ID: 18610755
[No Abstract] [Full Text] [Related]
2. [++UKPDS Study. Metformin in obese patients with Type 2 diabetes (UKPDS 340].
Janka HU
Internist (Berl); 2000 Jul; 41(7):688-9. PubMed ID: 10929259
[No Abstract] [Full Text] [Related]
3. Metformin as first choice in oral diabetes treatment: the UKPDS experience.
Holman R
Journ Annu Diabetol Hotel Dieu; 2007; ():13-20. PubMed ID: 18613325
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51).
Clarke P; Gray A; Adler A; Stevens R; Raikou M; Cull C; Stratton I; Holman R;
Diabetologia; 2001 Mar; 44(3):298-304. PubMed ID: 11317659
[TBL] [Abstract][Full Text] [Related]
5. UKPDS and beyond: into the next millennium. United Kingdom Prospective Diabetes Study.
Krentz AJ
Diabetes Obes Metab; 1999 Jan; 1(1):13-22. PubMed ID: 11221807
[No Abstract] [Full Text] [Related]
6. [Metformin in the UKPDS study. Metabolic and vascular results].
Basin C; Isnard F
Journ Annu Diabetol Hotel Dieu; 1999; ():243-61. PubMed ID: 10732421
[No Abstract] [Full Text] [Related]
7. [Therapeutic renaissance. Biguanides in type-2 diabetes: metformin].
Neye H
Pharm Unserer Zeit; 2002; 31(3):264-70. PubMed ID: 12071123
[No Abstract] [Full Text] [Related]
8. Applying some UK Prospective Diabetes Study results to Switzerland: the cost-effectiveness of intensive glycaemic control with metformin versus conventional control in overweight patients with type-2 diabetes.
Palmer AJ; Sendi PP; Spinas GA
Schweiz Med Wochenschr; 2000 Jul; 130(27-28):1034-40. PubMed ID: 10953853
[TBL] [Abstract][Full Text] [Related]
9. Metformin: from mechanisms of action to therapies.
Foretz M; Guigas B; Bertrand L; Pollak M; Viollet B
Cell Metab; 2014 Dec; 20(6):953-66. PubMed ID: 25456737
[TBL] [Abstract][Full Text] [Related]
10. Pioglitazone/metformin (Actoplus met).
Med Lett Drugs Ther; 2006 Jan; 48(1227):9-11. PubMed ID: 16444136
[No Abstract] [Full Text] [Related]
11. Type 2 diabetes and metformin. First choice for monotherapy: weak evidence of efficacy but well-known and acceptable adverse effects.
Prescrire Int; 2014 Nov; 23(154):269-72. PubMed ID: 25954799
[TBL] [Abstract][Full Text] [Related]
12. Sitagliptin/metformin (Janumet) for type 2 diabetes.
Med Lett Drugs Ther; 2007 Jun; 49(1262):45-7. PubMed ID: 17541377
[No Abstract] [Full Text] [Related]
13. [Insulin sparing and metabolic control with metformin-insulin combination].
Isnard F
Journ Annu Diabetol Hotel Dieu; 1997; ():305-25. PubMed ID: 9296986
[No Abstract] [Full Text] [Related]
14. Metformin: diamonds are forever.
Papanas N; Maltezos E; Mikhailidis DP
Expert Opin Pharmacother; 2009 Oct; 10(15):2395-7. PubMed ID: 19678795
[TBL] [Abstract][Full Text] [Related]
15. Metformin: the past, presence, and future.
Alušík Š; Paluch Z
Minerva Med; 2015 Aug; 106(4):233-8. PubMed ID: 25532538
[TBL] [Abstract][Full Text] [Related]
16. Implications of the United Kingdom prospective diabetes study for patients with obesity and type 2 diabetes.
Genuth S
Obes Res; 2000 Mar; 8(2):198-201. PubMed ID: 10757207
[No Abstract] [Full Text] [Related]
17. Metaglip and Avandamet for type 2 diabetes.
Med Lett Drugs Ther; 2002 Dec; 44(1146):107-9. PubMed ID: 12500153
[No Abstract] [Full Text] [Related]
18. Seeing what you want to see in randomised controlled trials: versions and perversions of UKPDS data. United Kingdom prospective diabetes study.
McCormack J; Greenhalgh T
BMJ; 2000 Jun; 320(7251):1720-3. PubMed ID: 10864554
[No Abstract] [Full Text] [Related]
19. Cost-utility analysis of intensive blood glucose control with metformin versus usual care in overweight type 2 diabetes mellitus patients in Beijing, P.R. China.
Xie X; Vondeling H
Value Health; 2008 Mar; 11 Suppl 1():S23-32. PubMed ID: 18387063
[TBL] [Abstract][Full Text] [Related]
20. [Metformin in type 2 diabetes: what if we get it wrong?].
Boussageon R
Presse Med; 2013 Feb; 42(2):132-3. PubMed ID: 23159535
[No Abstract] [Full Text] [Related]
[Next] [New Search]
